September 2, 2010 – 8:33 pm
New drugs not only offer hope, but possibly a better quality of life, for those awaiting new treatments. However, new drug approvals can also spark controversy. The FDA approved 17 new drugs this summer (June-August 2010). Many offer new promise, and one in particular promises a great deal of future debate.Since nearly one in three Americans has high blood pressure, it isn't surprising that two of the 17 newly approved drugs are antihypertensives. The most recently approved drug is Tekamlo (aliskiren and amlodipine) from Novartis, a single-pill combination drug for high blood pressure. Tribenzor is a new three-in-one combination drug that is taken once-daily to treat high blood pressure. The most controversial newly approved drug is the emergency co…
September 1, 2010 – 7:54 am
COLORADO SPRINGS, Colo., Sept. 1, 2010 (GLOBE NEWSWIRE) — Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment. In this multi-billion dollar market, this is very encouraging news for Cannabis Science shareholders as even small doses of cannabis provided relief from chronic, neuropathic pain, which may be caused by physical injuries or by anti-viral drugs used to treat HIV/AIDS. Neuropathic pain is also common in cancer patients as a direct result of the cancer, or as a side effect of chemotherapy, radiation or surgery. (Source: Medical News (via PRIMEZONE)…
September 1, 2010 – 7:01 am
NewsScan #68 includes recently published NIDA-supported research on a variety of issues, including PTSD and marijuana use, how synapses are formed, the effect of family-based interventions on Hispanic youth, a new approach to developing pain relievers, the effect of constructive parenting behaviors, cocaine addiction treatment, how the genes in zebrafish advance knowledge of nicotine addiction and memories and nicotine use. (Source: National Institutes of Health (NIH) News Releases)
August 19, 2010 – 8:00 am
FAIRFIELD, Conn., Aug. 19, 2010 (GLOBE NEWSWIRE) — Competitive Technologies, Inc. (NYSE Amex:CTT) today announced that the NYSE Amex (the Exchange) has rescheduled the previously postponed delisting hearing for August 25, 2010. The Company is working to finalize the sale of two million shares of CTT common stock to Crisnic Fund. The funds raised from this sale are expected to provide CTT with capital to increase shareholder equity required to retain the Exchange listing, and to more aggressively sell its non-invasive Calmare(r) Pain Therapy Treatment device (Source: Medical News (via PRIMEZONE))
August 17, 2010 – 2:31 am
Oh, and I guess there’s the minor matter of the make or break scan.
I’ll let you off of the hook at the beginning, if you like, and spare all but the deeply curious the tale of my approach to standardised interview questions. I am apparently the moderately relieved owner of on 16mm follicle after a pain-in-the-abdomen 14 days of 33 IU of the good stuff.
Who said I wasn’t a cheap date?
I’m probably triggering tomorrow and THEN all I have to try and do is not think thoughts of crumbling embryonic doom for a piffling five days. Piece of cake, that part.
The only snarfus of note was tonight when I realised that I had cleverly made a colossal cock up with the remaining amount of purego.n because the pen jammed on me last night, and in the process of figuring out wh…
August 5, 2010 – 12:15 pm
SAN MATEO, Calif., Aug. 5, 2010 (GLOBE NEWSWIRE) — Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that management will present at the Bank of America Merrill Lynch Pharmaceuticals Conference in New York on Thursday, August 12th. (Source: Medical News (via PRIMEZONE))
Scanning the genomes of more than 100,000 people from all over the world, scientists report the largest set of genes discovered underlying high cholesterol and high triglycerides — the major risk factors for coronary heart disease, the nation’s number one killer. Taken together, the gene variants explain between a quarter and a third of the inherited portions of cholesterol and triglyceride measured in the blood. The research, representing scientists from 17 countries, appears in two papers in the Aug. 5 issue of Nature. (Source: National Institutes of Health (NIH) News Releases)
Denizens of the Internet, just in case you wondered (although I guess you’ve all probably figured out that owning two screaming two year olds means that stabbing oneself with teeny-tiny doses of FSH is rather less of a dramatic affair the 4th transfer around) I’m stimming.
Apparently.
I mean, I’ve been jabbing for DAYS now and sometimes I’m still surprised that I get the right end into my flabby gut, what with all the leg pulling and yelling for ‘Mama, NOW!’.
As I recall, the LAST time I did this, there was a little less flab to choose from and a lot less distraction. Needle Time was a serious time Chez MII. It’s somewhere between the fifth verse of the Hokey Pokey song and bedtime these days and usually also right after I’ve burned my han…
FAIRFIELD, Conn., Aug. 2, 2010 (GLOBE NEWSWIRE) — Competitive Technologies, Inc. (NYSE Amex:CTT) announced that McKinney Regional Cancer Care Center, a private physician oncology practice based in McKinney, TX, is the first cancer center in Texas treating with CTT’s Calmare(r) Pain Therapy Treatment medical device. Patients suffering from pain related to cancer are being treated under the direction of medical oncologist Dennis Birenbaum, M.D. (Source: Medical News (via PRIMEZONE))
FAIRFIELD, Conn., July 30, 2010 (GLOBE NEWSWIRE) — Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that Commonwealth Pain Specialists, the premier pain management center in Richmond and Central Virginia, is treating patients suffering from chronic, intense neuropathic pain using CTT’s Calmare(r) Pain Therapy medical device. (Source: Medical News (via PRIMEZONE))
Subscribe to feed